Asthma and COPD Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The report covers Asthma Devices Market Growth and the market is segmented by Product (Inhaler and Nebulizer), Indication (Asthma and Chronic Obstructive Pulmonary Disease), and Geography (North America, Europe, Asia-pacific, Middle East and Africa, and South America). The market provides the value (in USD million) for the above-mentioned segments.

Asthma and COPD Devices Market Size

Asthma and COPD Devices Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 5.20 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration High

Major Players

Asthma and COPD Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Asthma and COPD Devices Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Asthma and COPD Devices Market Analysis

The asthma and COPD devices market is projected to register a CAGR of 5.2% during the forecast period (2022-2027).

The impact of acute COVID-19 on people with asthma appears complex, being moderated by multiple interacting disease-specific, demographic, and environmental factors. As per the survey conducted in October 2020 on "Impact of COVID-19 on people with asthma: a mixed-methods analysis from a United Kingdom-wide survey", the COVID-19 group reported increased inhaler use and worse asthma management compared with those not reporting COVID-19. Besides, as per the article published in November 2021 on "Influence of the first wave of COVID-19 on asthma inhaler prescriptions", at the beginning of the COVID-19 pandemic, there were major concerns regarding the huge demand for asthma inhalers. Using the primary-care medical records for 614,700 asthma patients between January and June 2020, it was found that there was a substantial increase in inhalers solely in March 2020.

Furthermore, another article published in July 2020 on "Inhalers Safe During COVID-19 Pandemic" stated that patients with asthma and chronic obstructive pulmonary disease are typically prescribed inhaled and oral corticosteroids with inhalers to prevent attacks. The demand for inhalers had soared 400% during the pandemic, which led to shortages in the United Kingdom. The Department of Health and Social Care stated that steroid inhaler manufacturers were experiencing significant demand as people in the United Kingdom tried to stock up considering the COVID-19 pandemic, causing distressing shortages. Hence, such incidents bolstered the demand for asthma and COPD devices during the pandemic phase.

The primary factors that are driving the market growth include an increase in the burden of asthma and COPD, technological advancements, and the growing geriatric population. The substantial increase in prevalence and incidence of asthma has led to an increase in the patient population, which has, in turn, increased the demand for these devices. According to the World Health Organization (WHO) 2021 factsheet, asthma is a major non-communicable disease (NCD), affecting both children and adults. Globally, it affected an estimated 262 million people in 2019 and caused 461,000 deaths. Also, as per the European Respiratory Society's (ERS) research study titled "An estimate of the European prevalence of COPD in 2050", published in 2020, ERS estimated that there were 36,580,965 Europeans with COPD, and the number is projected to reach 49,453,852 people by the year 2050.

Likewise, the increasing geriatric population around the world is expected to boost the market's growth. As per the National Institute of Health, in 2021, the United States population aged 65 years and above is projected to nearly double over the next three decades, from 48 million in 2015 to 88 million by 2050. The global population aged 80 years and above is expected to more than triple between 2015 and 2050, from 126.5 million to 446.6 million, respectively. This population group in some Asian and Latin American countries is predicted to quadruple by 2050. Therefore, owing to the fact that asthma is a broadly prevalent disease found in people over age 65 and that asthma in older adults can cause serious health issues if not treated accurately, the rising geriatric population is expected to propel the market's growth during the forecast period.

Thus, due to the aforementioned factors, the market is anticipated to witness substantial growth over the coming years. However, inadequate reimbursement policies and stringent regulatory approvals for products are expected to hamper market growth.

Asthma and COPD Devices Market Trends

This section covers the major market trends shaping the Asthma & COPD Devices Market according to our research experts:

The Asthma Segment is Expected to Hold a Major Market Share in the Asthma and COPD Devices Market

Asthma is a major noncommunicable disease (NCD), affecting both children and adults, and is the most common chronic disease among children. In the United States, asthma is more common in adult women than adult men. According to the Centers for Disease Control and Prevention 2020 report, in the United States, approximately 25 million Americans have asthma. This equals to about 1 in 13 Americans, including 8% of adults and 7% of children. About 20 million United States adults aged 18 years and over have asthma. Also, according to the Asthma and Allergy Foundation of America (AAFA), in 2021, roughly 1 in 13 Americans had asthma, which is about 25 million people. As per the same source, about 5 million American children have asthma.

The growing prevalence of asthma worldwide, coupled with the activities of government organizations and NGOs in creating awareness and companies' R&D activities in advancing asthma device technologies, are some of the factors boosting the segment's growth. For instance, in March 2022, the United States Food and Drug Administration approved the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of two common pulmonary health conditions, including asthma in patients six years of age and older. Moreover, in July 2020, Novartis received approval for Enerzair Breezhaler, including the first digital companion (sensor and app) that can be prescribed alongside treatment for uncontrolled asthma in Europe.

Thus, these aforementioned factors are collectively driving the growth of the segment throughout the forecast period.

Asthma and COPD Devices Market : Estimated Number of Cases of Asthma, Senior Citizens (in million), in India, 2020-2050

North America is Expected to Hold a significant share in the Market and is Expected to do Same in the Forecast Period.

The North American asthma and COPD market are anticipated to have a significant share of the global market owing to the increasing burden of asthma and COPD coupled with well-established healthcare infrastructure and rising awareness. As per the government of Canada, chronic obstructive pulmonary disease (COPD) affected 453,700 and 488,100 people in 2019 and 2020, which is 7.2% and 7.5% of the total population, respectively. Also, as per the Office of Disease Prevention and Health Promotion (ODPHP) 2020, more than 25 million people in the United States have asthma, and approximately 14.8 million adults have been diagnosed with COPD.

As per the Asthma and Allergy Foundation of America (AAFA), on average, 11 people in the United States die from asthma each day. The same source further stated that in 2020, 4,145 people died from asthma. Almost all of these deaths could be prevented with the proper treatment and care. Asthma-related deaths increased for the first time in 20 years in 2020. As per the Illinois Department of Central Management Services, 2022, annual direct costs per patient in the United States are more than USD 3,000. Due to the high death rates associated with asthma and increasing investment in asthma treatment in this country, the market is expected to show significant growth in the future. Furthermore, the presence of key market players and the advancement of product technologies are fuelling the region's market growth. For instance, in March 2021, in Mexico and the United States, AstraZeneca PLC started a Phase III clinical trial to assess the efficacy and safety of budesonide/glycopyrronium/formoterol inhalers in adults and adolescents with severe asthma inadequately controlled with the standard of care. The trial is expected to be completed in September 2023.

Thus, the aforementioned factors are expected to drive the market's growth over the forecast period.

Asthma and COPD Devices Market- Growth Rate By Region

Asthma and COPD Devices Industry Overview

The Asthma and COPD devices market is highly competitive and consists of a few major players. Companies like AstraZeneca Plc., Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Merck & Co., and Philips Healthcare, among others, hold a substantial market share in the Asthma and COPD Devices market. Market players are adopting various strategies such as new product launches, partnerships, and collaborations to remain competitive in the marketplace.

Asthma and COPD Devices Market Leaders

  1. AstraZeneca

  2. Boehringer Ingelheim

  3. GlaxoSmithKline

  4. Merck & Co.

  5. Philips Healthcare

*Disclaimer: Major Players sorted in no particular order

Asthma and COPD Devices Market Concentration
Need More Details on Market Players and Competitors?
Download PDF

Asthma and COPD Devices Market News

  • In May 2022, Alkem launched its first inhalation device, "Innohaler", for asthma and COPD patients.
  • In January 2022, Life Wellness Healthcare announced a new update to its online store to ensure that COPD sufferers can alleviate symptoms at home. The AirPhysio device is now available for delivery across the United States with flexible payment plans.

Asthma and COPD Devices Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in Incidence and Prevalence of Asthma and COPD

      2. 4.2.2 Technological Advancements

      3. 4.2.3 Growing Geriatric Population

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Government Regulations for the Product Approval

      2. 4.3.2 Inadequate Reimbursement Policies

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Product

      1. 5.1.1 Inhaler

        1. 5.1.1.1 Metered Dose Inhalers

        2. 5.1.1.2 Dry Powder Inhalers

        3. 5.1.1.3 Soft Mist Inhalers

      2. 5.1.2 Nebulizer

        1. 5.1.2.1 Compressor Nebulizer

        2. 5.1.2.2 Ultrasonic Nebulizer

        3. 5.1.2.3 Mesh Nebulizer

    2. 5.2 By Indication

      1. 5.2.1 Asthma

      2. 5.2.2 Chronic Obstructive Pulmonary Disease

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca Plc.

      2. 6.1.2 Boehringer Ingelheim GmbH

      3. 6.1.3 Drive DeVilbiss Healthcare

      4. 6.1.4 GF Health Products

      5. 6.1.5 Glaxosmithcline PLC

      6. 6.1.6 Invacare Corporation

      7. 6.1.7 Merck & Company

      8. 6.1.8 Omron Healthcare

      9. 6.1.9 PARI Pharma

      10. 6.1.10 Philips Healthcare

      11. 6.1.11 Recipharm AB

      12. 6.1.12 Teva Pharmaceutical Industries Ltd.

      13. 6.1.13 Opko Health, Inc.

      14. 6.1.14 GF HEALTH PRODUCTS, INC.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Asthma and COPD Devices Industry Segmentation

As per the scope of the report, asthma is referred to as a chronic respiratory disease that blocks the airways of the lungs because of mucus production, inflammation, and tightening of muscles. Similarly, Chronic Obstructive Pulmonary Disease (COPD) is caused by the blockade of the airways, further resulting in difficulty in breathing owing to the primary cause of tobacco smoking. Asthma and COPD devices are the devices that are used to treat these aforementioned respiratory diseases. The Asthma and COPD Devices Market is Segmented by Product (Inhaler and Nebulizer), Indication (Asthma and Chronic Obstructive Pulmonary Disease), and Geography (North America, Europe, Asia-pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Product
Inhaler
Metered Dose Inhalers
Dry Powder Inhalers
Soft Mist Inhalers
Nebulizer
Compressor Nebulizer
Ultrasonic Nebulizer
Mesh Nebulizer
By Indication
Asthma
Chronic Obstructive Pulmonary Disease
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Asthma and COPD Devices Market Research FAQs

The Global Asthma and COPD Devices Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)

AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co. and Philips Healthcare are the major companies operating in the Global Asthma and COPD Devices Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Global Asthma and COPD Devices Market.

The report covers the Global Asthma and COPD Devices Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Asthma and COPD Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Asthma Devices Industry Report

Statistics for the 2024 Asthma Devices market share, size and revenue growth rate, created by Mordor Intelligenceā„¢ Industry Reports. Asthma Devices analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Asthma and COPD Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)